U.S., April 11 -- ClinicalTrials.gov registry received information related to the study (NCT06922539) titled 'Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer' on March 22.
Brief Summary: This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Small Cell Lung Cancer
Intervention:
DRUG: Fenretinide
3 + 3 study design with dose escalation
DRUG: Fenretinide
Expansion of dose-finding Phase 1a
Recruitment Status: NOT_YET_RECRUITING
Sponsor: SciTech Development, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....